{"disease":{"id":"plasma-cell-dyscrasias","name":"plasma cell dyscrasias"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03616483","title":"The Indiana Myeloma Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT07365059","title":"Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Qi deng","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}